What is the prognosis of chronic immune thrombocytopenia?

被引:0
|
作者
Calleja Gero, M. L. [1 ]
Sevilla, J. [1 ]
Madero, L. [1 ]
机构
[1] Hosp Infantil Univ Nino Jesus, Serv Pediat, Madrid, Spain
来源
ANALES DE PEDIATRIA | 2011年 / 74卷 / 05期
关键词
Chronic idiopathic thrombocytopenic purpura; Primary immune thrombocytopenia; Splenectomy; Remission; PURPURA; CHILDHOOD; CHILDREN; ERADICATION;
D O I
10.1016/j.anpedi.2010.09.035
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objectives: To analyse the characteristics of children with chronic ITP (chronic immune thrombocytopenia) in the Hospital Infantil Universitario Nino Jesus (HIUNJ) between 2003 and 2008. To also evaluate whether clinical variables as age, gender, initial platelet count, and treatment have any prognostic significance on the outcome of ITP. Patients and methods: Data were retrospectively collected from 288 patients diagnosed with "Purpura and other haemorrhagic illnesses". Forty-two out of these 288 satisfied the criteria for "chronic ITP". Results: Ten patients out of 42 (23.8%) achieved remission with splenectomy, and 25 (almost 60%) achieved it without splenectomy (14 were complete remissions and 11 were partial remissions). Eight patients (almost 20% of patients with chronic ITP) had spontaneous remissions between 6 and 12 months from initial diagnosis. None of the clinical variables analysed were related to the outcome of the disease and the prognosis of the disease. Conclusions: Almost 60% of children with chronic ITP achieve remission without treatment regardless of age, gender, initial treatment or platelet count. Splenectomy is one of the treatments with best results; however the high spontaneous recovery rate in children with cITP, the low percentage of bleeding, and the generally benign outcome should encourage delaying this as long as possible. As it is possible to have a remission between 6 and 12 months from the initial diagnosis, the term "chronic" should be reserved for patients with ITP lasting more than 1 year. (C) 2010 Asociacion Espanola de Pediatria. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:317 / 323
页数:7
相关论文
共 50 条
  • [41] Correction to: Fostamatinib: A Review in Chronic Immune Thrombocytopenia
    Julia Paik
    Drugs, 2021, 81 : 1361 - 1361
  • [42] Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia
    Celeste B. Burness
    Gillian M. Keating
    Karly P. Garnock-Jones
    Drugs, 2016, 76 : 869 - 878
  • [43] Comorbidities in patients with persistent or chronic immune thrombocytopenia
    Cheryl Enger
    Dimitri Bennett
    Ulla Forssen
    Patrick F. Fogarty
    Andrew T. McAfee
    International Journal of Hematology, 2010, 92 : 289 - 295
  • [44] INCLUSION BODY MYOSITIS AND CHRONIC IMMUNE THROMBOCYTOPENIA
    RIGGS, JE
    SCHOCHET, SS
    GUTMANN, L
    MCCOMAS, CF
    ROGERS, JS
    ARCHIVES OF NEUROLOGY, 1984, 41 (01) : 93 - 95
  • [45] ARE THE AUTOANTIBODIES IN CHRONIC IMMUNE THROMBOCYTOPENIA OF CLONAL ORIGIN
    STOCKELBERG, D
    JACOBSSON, S
    HOU, M
    SWOLIN, B
    KUTTI, J
    WADENVIK, H
    BLOOD, 1994, 84 (10) : A663 - A663
  • [46] Romiplostim for the treatment of adults with chronic immune thrombocytopenia
    Terrail, Nicolas
    EJHP PRACTICE, 2009, 15 (03): : 70 - 73
  • [47] Chronic immune thrombocytopenia. Egyptian experience
    El Husseiny N.M.
    El Sobky A.
    Khalaf A.M.
    Fateen M.
    El Demerdash D.M.
    Youssef H.
    Salah M.
    El Ghany S.E.S.A.
    El Husseiny S.
    Gamil M.
    Comparative Clinical Pathology, 2018, 27 (3) : 735 - 739
  • [48] IMMUNE THROMBOCYTOPENIA IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    KADEN, BR
    HAUCH, TW
    ROSSE, WF
    CLINICAL RESEARCH, 1977, 25 (03): : A408 - A408
  • [49] Chronic immune thrombocytopenia and semaphorin 5A
    Nomura, Shosaku
    THROMBOSIS RESEARCH, 2015, 136 (05) : 843 - 844
  • [50] Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia
    Burness, Celeste B.
    Keating, Gillian M.
    Garnock-Jones, Karly P.
    DRUGS, 2016, 76 (08) : 869 - 878